Active surveillance in intermediate-risk prostate cancer-Reference-Cited by-同舟云学术

Active surveillance in intermediate-risk prostate cancer

Published:2020-01-16 Issue:3 Volume:125 Page:346-354
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Klotz Laurence¹^ORCID

Affiliation:

1. Division of Urology; Sunnybrook Health Sciences Centre; University of Toronto; Toronto ON Canada

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14935/fullpdf

Reference58 articles.

1. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression;Choo;J Urol,2002

2. Active surveillance for the management of localized prostate cancer: guideline recommendations;Morash;Can Urol Assoc J,2015

3. CCOActive surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement;Chen;J Clin Oncol,2016

4. clinically localized prostate cancer: AUA/ASTRo/SUO guideline. Recommended approaches and details of specific care options;Sanda;J Urol,2018

5. National Collaborating Centre for Cancer Prostate Cancer: Diagnosis and Treatment. Clinical Guideline http://www.nice.org.uk/nicemedia/live/14348/66232/66232.pdf

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MRI at diagnostic versus confirmatory biopsy during MRI-based active surveillance of prostate cancer;Urologic Oncology: Seminars and Original Investigations;2024-10

2. Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing;The Prostate;2024-07-25

3. Interaction of patient age and high‐grade prostate cancer on targeted biopsies of MRI suspicious lesions;BJU International;2024-03-27

4. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer;Frontiers in Endocrinology;2024-02-07

5. Oncological Outcomes in Men With Favorable Intermediate Risk Prostate Cancer Enrolled in Active Surveillance;In Vivo;2024